{
    "id": "professional_medicine-255",
    "question": "A previously healthy 24-year-old woman who is a college student comes to the office because of a 6-month history of abdominal bloating, upper abdominal discomfort, and constipation. The symptoms are more severe when she is preparing for examinations but improve after bowel movements. She takes no medications. She does not smoke or use illicit drugs. She drinks alcoholic beverages occasionally. She is 160 cm (5 ft 3 in) tall and weighs 57 kg (125 lb); BMI is 22 kg/m2 . Her pulse is 72/min, and blood pressure is 100/72 mm Hg. Physical examination, including digital rectal examination, shows no other abnormalities. A complete blood count and serum electrolyte concentrations are within the reference ranges. A urease breath test result is negative. Upper and lower endoscopies show no abnormalities. Which of the following is the most appropriate pharmacotherapy for this patient?",
    "options": {
        "A": "Azathioprine",
        "B": "Infliximab",
        "C": "Lubiprostone",
        "D": "Mesalamine"
    },
    "answer": "C",
    "predict": "{\"step_by_step_thinking\": \"To approach this case, we should consider the patient's symptoms and laboratory results. The patient presents with abdominal bloating, upper abdominal discomfort, and constipation, which are more severe before bowel movements and improve after bowel movements. These symptoms are suggestive of irritable bowel syndrome (IBS), particularly the constellation of abdominal pain and changes in bowel habits. The absence of blood in the stool, normal complete blood count and serum electrolyte concentrations, and negative urease breath test rule out other potential causes such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and small intestine bacterial overgrowth (SIBO). The normal upper and lower endoscopies further support this diagnosis. Given the diagnosis of IBS, the primary treatment goals are to manage symptoms, improve quality of life, and prevent complications. The pharmacotherapy options listed can be evaluated as follows: Azathioprine is an immunosuppressive medication typically used in the treatment of inflammatory bowel disease (IBD), which is not indicated in this case given the negative urease breath test and normal endoscopies. Infliximab is a biologic medication used to treat IBD, including ulcerative colitis and Crohn's disease. It is not typically used as a first-line treatment for IBS. Lubiprostone is a chloride channel activator that works by increasing intestinal fluid secretion, promoting bowel movements, and improving constipation symptoms. It is an appropriate treatment option for patients with IBS-C (constipation-predominant IBS) or mixed IBS. Mesalamine is an aminosalicylate that is used to treat IBS-D (diarrhea-predominant IBS) and IBD. It is not indicated in this case, as the patient does not have diarrhea or evidence of IBD. Therefore, based on the patient's symptoms and diagnostic results, the most appropriate pharmacotherapy is Lubiprostone.\", \"answer_choice\": \"C\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 32.88150143623352
}